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dependence on the egg supply and provide greater produc-
tion ﬂexibility.
doi:10.1016/j.ijid.2010.02.1508
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Emerging Trends: Vaccines in late development
R.L. Atmar
Baylor College of Medicine, Houston, TX, USA
A number of strategies are being pursued to increase the
availability of and to improve the immunogenicity, efﬁcacy,
and effectiveness of seasonal inﬂuenza vaccines. Many of
these approaches have led to vaccine candidates that are
in the late stages of clinical evaluation (i.e., Phase 3 trials)
or that have been recently licensed. Approaches to increase
the availability of inﬂuenza vaccines in the United States
include the licensure of vaccines approved in other countries
and the production of inﬂuenza virus antigens by cell cul-
ture (eg, canine kidney cells and Vero cells) rather than by
growth in embryonated eggs. Some cell culture-derived vac-
cines are approved in Europe. The inﬂuenza hemagglutinin is
partially puriﬁed from whole virus in currently licensed vac-
cines. Another approach is the production of inﬂuenza virus
hemagglutinin with a baculovirus expression system. Alter-
native routes of immunization have also been explored, and
an intradermally administered vaccine has recently been
approved for use in persons 60 years of age and older in
Europe. Improved vaccine immunogenicity and efﬁcacy may
be attained through the use of adjuvants or higher doses
of hemagglutinin. Although several adjuvanted inﬂuenza
virus vaccines are approved in other countries, none are
licensed in the United States. However, oil-in-water adju-
vants are in advanced stages of evaluation. A high-dose (60
mcg hemagglutinin) trivalent inﬂuenza vaccine has recently
been licensed based upon its superior immunogenicity com-
pared with the standard dose (15 mcg hemagglutinin), to be
used in persons 65 years of age and older. Phase 4 studies of
the high-dose vaccine are under way to determine whether
the improved immunogenicity is associated with increased
vaccine efﬁcacy and effectiveness.
doi:10.1016/j.ijid.2010.02.1509
Traveler’s diarrhea and enteric diseases of Latin
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Epidemiology of Traveler’s Diarrhea
A. McCarthy
Ottawa Hospital, Ottawa, ON, Canada
This presentation will provide a review of etiologies and
risk factors for diarrhea in those visiting Latin America and
will provide some comparison with travelers to other desti-
nations.
doi:10.1016/j.ijid.2010.02.1510
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raveler’s Diarrhea: Prevention and Treatment
. Steffen
University of Zurich, Zurich, Switzerland
Different options for the prevention of travelers’ diarrhea
TD) exist. Risk reduction is possible by implementing the
azard Analysis Critical Control Point System or by improve-
ent of the local infrastructure. To abandon travel plans
r to abstain from potentially contaminated food and bev-
rages is not attractive. Both a cholera and a candidate
T-ETEC transcutaneous patch vaccine have been shown to
revent TD by LT-ETEC strains, possibly by other pathogens.
mong drugs suggested for chemoprophylaxis, probiotics
howed at best a low protective efﬁcacy rate; bismuth sub-
alicylate was modestly effective. Many older antibacterial
gents are obsolete because of antimicrobial resistance by
revalent enteric bacterial pathogens. The fear of systemic
eactions has limited the prescription of ﬂuoroquinolones.
oorly absorbed antibiotics, mainly rifaximin, are more
ttractive for compliant travelers.
As no current prophylactic measure is satisfactory, (self)-
herapy of TD remains an important option (travel kit!). Only
ew still recommend to wait for spontaneous cure; rapid
elief is often important as incapacitation and the necessity
o change travel plans have a great impact. Probiotics and
harcoal have been demonstrated to offer no clinically rel-
vant beneﬁt. Oral rehydration solutions have no effect on
he duration or amount of diarrhea, but they are essential in
aediatric patients and senior travelers. Antimotility agents
ffer fast relief, but they are contraindicated in dysentery,
lso they are often followed by a period of constipation.
Antimicrobial agents, mainly quinolones and particularly
n SE-Asia also azithromycin, have been used in this decade,
lthough there is only limited recent data on the frequency
f resistance from analysis of TD stool samples on all con-
inents. The non-absorbed rifamycin-derivative rifaximin —
ith a broad antimicrobial spectrum and a tolerance pro-
le similar to placebo — has been demonstrated in patients
ith TD to be as effective as ciproﬂoxacine, but this only in
on-invasive cases of TD.
oi:10.1016/j.ijid.2010.02.1511
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elminths of Latin America
. Coyle
Albert Einstein College of Medicine, Bronx, NY, USA
This session will focus on intestinal helminths. Ascaris
umbricoides is among the most prevalent of parasitic
nfections in humans. Most patients are asymptomatic or
xperience mild abdominal pain. Children have the high-
st intensity of infections and generally present with more
evere clinical manifestations. The most common clinical
yndromes of ascariasis are pneumonitis, intestinal, bil-
ary and pancreatic obstruction. Ascariasis adversely affects
rowth, development, and nutritional status of children.
nother helminth, Hookworm, is particularly troubling for
hildren and women of reproductive age who are vulnerable
